Supplementary Figure 2 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non–small Cell Lung Cancer

Supplementary Figure 2. ROS1 TKI in combination with SHP099 (A) Immunoblots of the indicated proteins in HCC78 and ABC-20 cells treated for 24 h with DS-6051b (Ds, 100 nM) with or without SHP099 (SHP, 5 µM). Comb, combination. (B) RAS-GTP assay in H3122 cells treated with alectinib (Alec, 100 nM), ABC-20 cells treated with crizotinib (Cri, 1 µM) and HCC827 cells treated with osimertinib (Osi, 100 nM) for 24 h. All cell lines were also treated or not with SHP099 (SHP, 5 µM). Comb, combination. (C) Cell viability curves for cell lines treated with DS-6051b (DS) alone (circles), SHP099 (SHP) alone (triangles) or DC6051b and SHP099 (5 µM) (squares). All drugs were loaded for 96 h. Error bars represent the standard error.